drug

exemestane

1 story · latest Oct 14, 2026

Follow exemestane. Every new filing, FDA action, and trial change, in your feed and a morning email, each linked to its source.

Follow free for 14 daysNo card.

Status: FDA approved Oct 1999 · NDA020753
Brand: Aromasin
Trials: 9 registered trials in coverage

Relationships

Developed by Viatris Inc.

Timeline

Lilly terminates Phase 1 atopic dermatitis trial; registers pediatric tirzepatide Phase 3

Oct 14Weekly roundup, 4 itemsabemaciclib Eli Lilly

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.